hera Neuroactive Kynurenines as Pharmacological Targets: New Experimental Tools and Exciting Therapeutic Opportunities [75th Anniversary Celebration Collection Special Section] By pharmrev.aspetjournals.org Published On :: 2024-10-16T07:40:25-07:00 Both preclinical and clinical studies implicate functional impairments of several neuroactive metabolites of the kynurenine pathway (KP), the major degradative cascade of the essential amino acid tryptophan in mammals, in the pathophysiology of neurologic and psychiatric diseases. A number of KP enzymes, such as tryptophan 2,3-dioxygenase (TDO2), indoleamine 2,3-dioxygenases (IDO1 and IDO2), kynurenine aminotransferases (KATs), kynurenine 3-monooxygenase (KMO), 3-hydroxyanthranilic acid oxygenase (3-HAO), and quinolinic acid phosphoribosyltransferase (QPRT), control brain KP metabolism in health and disease and are therefore increasingly considered to be promising targets for the treatment of disorders of the nervous system. Understanding the distribution, cellular expression, and regulation of KP enzymes and KP metabolites in the brain is therefore critical for the conceptualization and implementation of successful therapeutic strategies. Significance Statement Studies have implicated the kynurenine pathway of tryptophan in the pathophysiology of neurologic and psychiatric diseases. Key enzymes of the kynurenine pathway regulate brain metabolism in both health and disease, making them promising targets for treating these disorders. Therefore, understanding the distribution, cellular expression, and regulation of these enzymes and metabolites in the brain is critical for developing effective therapeutic strategies. This review endeavors to describe these processes in detail.: Full Article
hera Enzyme Replacement Therapy for CLN2 Disease: MRI Volumetry Shows Significantly Slower Volume Loss Compared with a Natural History Cohort [CLINICAL PRACTICE] By www.ajnr.org Published On :: 2024-11-07T15:14:12-08:00 BACKGROUND AND PURPOSE: Neuronal ceroid lipofuscinoses are a group of neurodegenerative disorders. Recently, enzyme replacement therapy (ERT) was approved for neuronal ceroid lipofuscinosis type 2 (CLN2), a subtype of neuronal ceroid lipofuscinoses. The aim of this study was to quantify brain volume loss in CLN2 disease in patients on ERT in comparison with a natural history cohort using MRI. MATERIALS AND METHODS: Nineteen (14 female, 5 male) patients with CLN2 disease at 1 UK center were studied using serial 3D T1-weighted MRI (follow-up time, 1–9 years). Brain segmentation was performed using FreeSurfer. Volume measurements for supratentorial gray and white matter, deep gray matter (basal ganglia/thalami), the lateral ventricles, and cerebellar gray and white matter were recorded. The volume change with time was analyzed using a linear mixed-effects model excluding scans before treatment onset. Comparison was made with a published natural history cohort of 12 patients (8 female, 4 male), which was re-analyzed using the same method. RESULTS: Brain volume loss of all segmented brain regions was much slower in treated patients compared with the natural history cohort. For example, supratentorial gray matter volume in treated patients decreased by a mean of 3% (SD, 0.74%) (P < .001) annually compared with an annual volume loss of a mean of 16.8% (SD, 1.5%) (P < .001) in the natural history cohort. CONCLUSIONS: Our treatment cohort showed a significantly slower rate of brain parenchymal volume loss compared with a natural history cohort in several anatomic regions. Our results complement prior clinical data that found a positive response to ERT. We demonstrate that automated MRI volumetry is a sensitive tool to monitor treatment response in children with CLN2 disease. Full Article
hera Optimal Endovascular Therapy Technique for Isolated Intracranial Atherothrombotic Stroke-Related Large-Vessel Occlusion in the Acute-to-Subacute Stage [CLINICAL PRACTICE] By www.ajnr.org Published On :: 2024-11-07T15:14:12-08:00 BACKGROUND AND PURPOSE: Reocclusion after treatment is a concern in endovascular therapy for isolated intracranial atherothrombotic stroke-related large-vessel occlusion (AT-LVO). However, the optimal endovascular therapy technique for AT-LVO has not yet been investigated. This study evaluated the optimal endovascular therapy technique for AT-LVO in a real-world setting. MATERIALS AND METHODS: We conducted a historical, multicenter registry study at 51 centers that enrolled patients with AT-LVO. We divided the patients into 3 groups based on the endovascular therapy technique: mechanical thrombectomy alone, percutaneous transluminal angioplasty (PTA), and stent deployment. Mechanical thrombectomy alone was classified into the mechanical thrombectomy-only group; PTA and mechanical thrombectomy–PTA, into the PTA group; and mechanical thrombectomy–stent deployment, mechanical thrombectomy–PTA–stent deployment, PTA–stent deployment, and stent deployment–only into the stent group. The primary outcome was incidence of reocclusion of the treated vessels within 90 days of endovascular therapy completion. RESULTS: We enrolled 770 patients and analyzed 509 patients. The rates in the mechanical thrombectomy-only, PTA, and stent deployment groups were 40.7%, 44.4%, and 14.9%, respectively. Incidence rate of residual stenosis >70% of final angiography was significantly higher in the mechanical thrombectomy-only group than in the PTA and stent deployment groups (mechanical thrombectomy-only versus PTA versus stent deployment: 34.5% versus 26.3% versus 13.2%, P = .002). Reocclusion rate was significantly lower in the PTA group than in the mechanical thrombectomy-only group (adjusted hazard ratio, 0.48; 95% CI, 0.29–0.80). Of the patients, 83.5% experienced reocclusion within 10 days after endovascular therapy. Alarmingly, a substantial subset (approximately 62.0%) of patients experienced reocclusion within 2 days of endovascular therapy. Incidence of mRS scores of 0–2 ninety days after endovascular therapy was not significantly different among the 3 groups. Incidences of symptomatic intracranial hemorrhage, any other intracranial hemorrhage, and death were not significantly different. CONCLUSIONS: Incidence rate of reocclusion was significantly lower in the PTA group than in the mechanical thrombectomy-only group. We found no meaningful difference in reocclusion rates between the stent deployment and mechanical thrombectomy-only groups. In Japan, glycoprotein IIb/IIIa inhibitors are not reimbursed. Therefore, PTA might be the preferred choice for AT-LVOs due to the higher reocclusion risk with mechanical thrombectomy-only. Reocclusion was likely to occur within 10 days, particularly within 2 days post-endovascular therapy. Full Article
hera CGRP therapy in primary care for migraine: prevention and acute medication By bjgp.org Published On :: 2024-10-31T16:05:26-07:00 Full Article
hera The CheckMate 816 trial: a milestone in neoadjuvant chemoimmunotherapy of nonsmall cell lung cancer By breathe.ersjournals.com Published On :: 2024-11-12T00:25:08-08:00 Advancements in immunotherapy in the perioperative setting have revolutionised the treatment of resectable nonsmall cell lung cancer (NSCLC). Here we present the methodology and results of the clinical trial CheckMate 816 demonstrating the benefit of neoadjuvant therapy with nivolumab plus chemotherapy compared with chemotherapy alone. Furthermore, this article discusses the implications for future practice in resectable NSCLC and the need for future research. Full Article
hera Karen Pence to outline goals for art therapy initiative By www.pbs.org Published On :: Wed, 18 Oct 2017 12:33:59 +0000 File photo of Karen Pence (right) by Jonathan Ernst/Reuters WASHINGTON — When Karen Pence found out that an art therapist in hurricane-ravaged Puerto Rico couldn’t afford the clay her clients needed, she sprang into action. A trained watercolor artist and advocate of the little-known mental health profession, Vice President Mike Pence’s wife went to the Virginia art supply store she frequented when they lived in the state during his tenure in Congress, bought 120 pounds of self-drying clay and packed it aboard Air Force Two for their flight down to survey the damage. “She cleaned him out,” the vice president said of the store’s owner. Mrs. Pence made art therapy her cause ever since she first learned about it more than a decade ago. She has visited numerous art therapy programs, both in the U.S. and abroad, and on Wednesday in Florida, nine months into the administration, she planned to formally announce the goals for her art therapy initiative. She wants to help people understand the difference between art therapy and arts and crafts, and to grasp that art therapy is a viable option for treating trauma, injury and other life experiences. She also wants to encourage young people to choose art therapy as a career. “I don’t think that a lot of people understand the difference between therapeutic art and art therapy,” Mrs. Pence, a trained watercolor artist, told The Associated Press in an exclusive interview before the announcement at Florida State University in Tallahassee. The school has an art therapy program she described as “tremendous.” Blabbing to a girlfriend can be therapeutic, she explained, but it is not the same as art therapy, which has three elements: a client, a trained therapist and art. READ MORE: VP Pence’s wife aims to raise awareness about art therapy As passionate as she is about raising art therapy’s profile, other issues help make Karen Pence tick, too. One of them is helping military families, especially spouses. Her only son, Michael, is in the Marines. There’s also her interest in honeybees. Mrs. Pence installed a beehive on the grounds of the U.S. Naval Observatory, where the vice president’s official residence is located, to help call attention to a decline in managed bee colonies that officials say could negatively affect U.S. agricultural production. She had a beehive at the Indiana governor’s residence for the same reason. Now 60 and married to the vice president since 1985, Mrs. Pence has long been viewed as one of her husband’s most trusted political advisers. They are often together on trips, at the White House, or at the observatory, almost always holding hands. Since returning to Washington in January (the family lived in the area when her husband served in Congress), she has accompanied the vice president on goodwill tours of Europe, Asia and Latin America, as well as trips to survey recent hurricane damage in Texas, Puerto Rico and the U.S. Virgin Islands. She tries to visit art therapy programs wherever she goes. Journalists who travel with Pence often keep an eye out for his wife; she often brings them cookies when he ventures back to the press cabin for small talk. READ MORE: Devastated Puerto Rico needs unprecedented aid, says governor She’s even done a little campaigning, urging Virginians to vote next month for Ed Gillespie in what’s viewed as a tight gubernatorial race. “It really makes a difference, I can tell you. Nobody thought that we were going to win,” she said, an apparent reference to the Trump-Pence ticket. The vice president often refers to his wife as the family’s “prayer captain.” She has led congregations in prayer during their hurricane-damage trips. “We’re people of faith so we just try and approach everything with prayer,” Mrs. Pence said from her sunny, second-floor office in the Eisenhower Executive Office Building in the White House complex, where she and her staff enjoy coveted views of the Washington Monument and Jefferson Memorial. Art therapy drawings given as gifts adorn the outer office. She proudly displayed several of her paintings, including of the Capitol dome, the vice president’s residence, a Ball canning jar-turned-flower vase, a cardinal bird and a pink peony. She turns many of her watercolors into prints and boxed notecards that she gifts to art therapists she meets. Except for myriad pets, including two cats, a dog and a rabbit named Marlon Bundo, the Pences are empty nesters. Their son and two adult daughters are off on their own. “I think for us this is a good time in our life for this role because our kids are out of college. They’re living their own lives,” Mrs. Pence said. She’s also launching a blog in conjunction with Wednesday’s announcement to chronicle her visits to art therapy programs. The post Karen Pence to outline goals for art therapy initiative appeared first on PBS NewsHour. Full Article Art therapy karen pence Puerto Rico
hera Hera mission set to revisit asteroid after NASA's redirection test By www.newscientist.com Published On :: Fri, 04 Oct 2024 12:48:43 +0100 The European Space Agency is sending a probe to get a closer look at the asteroid Dimorphos, which had its orbit altered by NASA’s DART mission in 2022 Full Article
hera ESA prepares Hera mission to investigate aftermath of NASA DART impact By www.newscientist.com Published On :: Mon, 19 Feb 2024 11:48:51 +0000 The European Space Agency's Hera spacecraft must be thoroughly tested before being sent to investigate the aftermath of the collision of NASA's DART probe with Dimorphos Full Article
hera More women seek testosterone therapy, prompted by influencers, docs say... By www.nbcnews.com Published On :: 2024-11-13T06:19:38Z More women seek testosterone therapy, prompted by influencers, docs say... (Third column, 11th story, link) Full Article
hera Ask Ash: Sex therapist answers tough reader questions By www.starobserver.com.au Published On :: Sun, 18 Dec 2016 10:16:53 +0000 I’ve been with my partner for three years and our sex life has suddenly died. Is it normal and how long should I go before I start questioning it? If sex ... The post Ask Ash: Sex therapist answers tough reader questions appeared first on Star Observer. Full Article Healthy Living Life + Style LUXE sex therapy
hera Innovative Models for Improving Access and Visibility for Specialty-Lite and Retail Therapies By feeds.feedblitz.com Published On :: Fri, 04 Oct 2024 11:23:00 +0000 Today’s guest post comes from Timothy Nielsen, Vice President of Customer Success at AssistRx. Timothy discusses the affordability and patient journey challenges of specialty-lite products for patients, manufacturers, and health care providers. He explains how AssistRx's Advanced Access Anywhere (AAA) solution streamlines processes for specialty-lite products and facilitates enrollment via a digital hub. To learn more, register for AssistRx's free webinar on October 8: Meet Your Patients Where They Are & Gain Visibility: Even at Retail. Read on for Timothy’s insights. Read more » Full Article Guest Post Sponsored Post
hera No More Delays: Accelerating Therapy Starts by Embedding Hub Services in Provider Workflows By feeds.feedblitz.com Published On :: Fri, 25 Oct 2024 05:00:00 +0000 Today’s guest post comes from Shabbir Ahmed, Chief Commercial Officer at CareMetx. Shabbir explains the barriers that providers face when dealing with branded portals for multiple products. He then maintains that patients can access new therapies more quickly when the manufacturer relies on a brand-agnostic hub connected to a large network of providers and integrated with the systems those providers use daily. To learn more, download CareMetx’s new 2024 Patient Services Report: Revealing Manufacturer Priorities: Patients Naturally Take Center Stage. Read on for Shabbir’s insights. Read more » Full Article Guest Post Sponsored Post
hera Bio-Thera and Gedeon Richter partner to commercialize Stelara biosimilar BAT2206 By www.gabionline.net Published On :: Tue, 05 Nov 2024 09:14:16 +0000 <p>In October 2024, China based Bio-Thera Solutions (Bio-Thera) and Hungary’s Gedeon Richter announced they have reached an exclusive commercialization and license agreement for BAT2206, a biosimilar candidate to Johnson & Johnson’s Stelara (ustekinumab).</p> Full Article
hera Everything you need to know about the COVID-19 therapy trials By www.pharmaceutical-journal.com Published On :: Mon, 15 Feb 2021 16:51 GMT Researchers around the world are working at record speed to find the best ways to treat and prevent COVID-19, from investigating the possibility of repurposing existing drugs to searching for novel therapies against the virus. Full Article
hera New drug cuts the risk of death in bladder cancer by 30% compared with chemotherapy, study suggests By www.pharmaceutical-journal.com Published On :: Thu, 18 Feb 2021 15:30 GMT A new type of drug that targets chemotherapy directly to cancer cells reduces the risk of death from the most common type of bladder cancer by 30%, a phase III trial in the New England Journal of Medicine has suggested. Full Article
hera ESMO Reflections: Glimmers of Hope with the Next Wave of I-O Therapies? By lifescivc.com Published On :: Thu, 10 Oct 2024 11:00:02 +0000 By Jonathan Montagu, CEO of HotSpot Therapeutics, as part of the From The Trenches feature of LifeSciVC HotSpot’s trip to Barcelona for the recent European Society of Medical Oncology (ESMO) Annual Meeting was no ‘European Vacation,’ but it was certainly The post ESMO Reflections: Glimmers of Hope with the Next Wave of I-O Therapies? appeared first on LifeSciVC. Full Article From The Trenches Portfolio news Science & Medicine
hera ‘Serial Killing’ Cell Therapy From Autolus Lands FDA Approval in Blood Cancer By medcitynews.com Published On :: Sun, 10 Nov 2024 17:32:00 +0000 Autolus Therapeutics’ Aucatzyl is now FDA approved for treating advanced cases of B-cell precursor acute lymphoblastic leukemia. While it goes after the same target as Gilead Sciences’ Tecartus, Autolus engineered its CAR T-therapy with properties that could improve safety, efficacy, and durability. The post ‘Serial Killing’ Cell Therapy From Autolus Lands FDA Approval in Blood Cancer appeared first on MedCity News. Full Article BioPharma Daily Legal Pharma acute lymphoblastic leukemia Aucatzyl Autolus Therapeutics biopharma nl blood cancer cancer CAR-T cell therapy FDA
hera Unlocking the Future of Radioligand Therapy: From Discovery to Delivering at Scale By medcitynews.com Published On :: Tue, 12 Nov 2024 14:50:00 +0000 As radiopharmaceuticals enter a new phase, industry leaders must rethink external services and internal capabilities to master the complexities of delivering advanced therapies. The post Unlocking the Future of Radioligand Therapy: From Discovery to Delivering at Scale appeared first on MedCity News. Full Article BioPharma Daily MedCity Influencers Pharma Pharmacy biopharma nl Cancer Treatment pharmaceuticals radioligand therapy RLT
hera Neurogene Gene Therapy Shows Signs of Efficacy in Small Study, But an Adverse Event Spooks Investors By medcitynews.com Published On :: Tue, 12 Nov 2024 20:50:12 +0000 Neurogene’s Rett syndrome gene therapy has preliminary data supporting safety and efficacy of the one-time treatment. But a late-breaking report of a serious complication in a patient who received the high dose sent shares of the biotech downward. The post Neurogene Gene Therapy Shows Signs of Efficacy in Small Study, But an Adverse Event Spooks Investors appeared first on MedCity News. Full Article BioPharma Daily biopharma nl Clinical Trials gene therapy Neurogene rare disease Rett syndrome
hera Despite COVID-19 Challenges Dental Therapy Had a Watershed 2020 and Is Poised to Grow By www.pewtrusts.org Published On :: Fri, 22 Jan 2021 10:21:00 -0500 2020 was a difficult year for dental providers as the COVID-19 pandemic swept across the country. When stay-at-home orders went into effect in the spring, dental offices closed their doors to all but emergency patients. Full Article
hera PTO Cancer Immunotherapy Fast Track By www.lifescienceslawblog.com Published On :: Wed, 06 Jul 2016 16:33:54 +0000 In response to President Obama’s National Cancer Moonshot initiative to eliminate cancer, the USPTO has launched the “Cancer Immunotherapy Pilot Program.” The Pilot Program provides an accelerated review for applications related to cancer immunotherapy and is set to launch in July 2016. According to the USPTO, this initiative: aims to cut the time it takes to...… Continue Reading Full Article Other National Cancer Moonshot Initiative Patents USPTO
hera Simple therapeutic ways to break the cycle of stress By www.asiaone.com Published On :: Sun, 10 Nov 2024 22:30:00 +0800 Life can sometimes feel like a never-ending cycle of stress and decisions. That's usually my weekdays in a nutshell: chasing deadlines, making tough calls, and hopping between meetings. When your brain feels like it's on overdrive, it's time to hit pause. Engaging in some therapeutic activities can give your mind the breather it desperately needs. The good news? They don't have to be complicated or time-consuming. Here are some that can work wonders for your mental clarity and overall well-being. Step outside for a walk Walking is one of the simplest ways to clear your mind. It's amazing what a little fresh air at your nearby PCN can do. Just stepping outside and getting those legs moving can shift your perspective in a matter of minutes — and burn a few calories too! Disconnect from your phone and enjoy the sights and sounds of the great outdoors. I find that a 30-min walk and a change of environment works wonders for me, helping me rationally dissect my worries, such as my crushing feelings of inadequacy at work. Full Article
hera Results of Hematology/Oncology Pharmacy Association and Eisai Inc. Survey Show 83 Percent of Patients Receiving Chemotherapy May Be Unnecessarily Suffering from Chemotherapy-induced Nausea and Vomiting - Time to Talk CINV� Video By www.multivu.com Published On :: 19 Oct 2015 15:42:00 EDT Time to Talk CINV� Video Full Article Healthcare Hospitals Medical Pharmaceuticals Supplementary Medicine Pharmaceuticals Broadcast Feed Announcements Survey Polls & Research MultiVu Video
hera Accelerated Partial Breast Irradiation with Brachytherapy Achieves Excellent Long-Term Toxicity and Cosmetic Outcomes - Robert Kuske, MD By www.multivu.com Published On :: 27 Oct 2015 15:58:00 EDT Robert Kuske, MD Full Article Biotechnology Healthcare Hospitals Medical Pharmaceuticals Medical Equipment Pharmaceuticals FDA Approval Clinical Trials Medical Discoveries MultiVu Video
hera St. Jude Children's Research Hospital� opens first proton therapy center for children - Proton Therapy at St. Jude By www.multivu.com Published On :: 14 Dec 2015 16:35:00 EST Proton therapy will be used to treat brain tumors, Hodgkin lymphoma and other solid tumors and is the most advanced form of radiation technology available to patients. Full Article Healthcare Hospitals Medical Pharmaceuticals New Products Services Children-related News Broadcast Feed Announcements MultiVu Video
hera Paralympic torch heralds landmark By www.bbc.co.uk Published On :: Thu, 01 Mar 2012 18:14:32 GMT The Paralympic torch design has a mirrored finish so its colour adapts to its surroundings and also shines. Full Article UK
hera From Party Drugs to Healing Tools - The Promise of Psychedelic Therapy! By www.medindia.net Published On :: medlinkPsychedelics/medlink, previously known as dangerous party drugs, are now being explored as addiction treatments, but extensive research is Full Article
hera Shielding Our Little Ones: The Uneven Reach of Infant Helmet Therapy By www.medindia.net Published On :: According to the July issue of Plastic and Reconstructive Surgery, a journal of the American Society of Plastic Surgeons (ASPS), helmet therapy is a highly Full Article
hera Hormone Therapy Slows Aging in Postmenopausal Women By www.medindia.net Published On :: medlinkHormone therapy/medlink (HT) may slow medlinkbiological aging/medlink in postmenopausal women, particularly those with lower socioeconomic Full Article
hera Menopause Magic: Hormone Therapy Fights Insulin Resistance By www.medindia.net Published On :: medlinkHormone therapy/medlink was found to be beneficial in reducing insulin resistance in postmenopausal women, revealed study (!--ref1--). h2What Full Article
hera Sleep Well, Mom-to-Be: Insomnia Therapy Lowers Postpartum Depression Risk By www.medindia.net Published On :: While poor sleep is common during and after pregnancy, Canadian researchers suggest cognitive behavioral therapy for insomnia (CBTi) as an effective solution. Full Article
hera Immunotherapy Gap: Addressing Racial Disparities in Breast Cancer Care By www.medindia.net Published On :: Black patients with bmedlinktriple-negative breast cancer/medlink (TNBC)/b received immunotherapy at significantly lower rates than white patients. Full Article
hera Enhancing CAR-T Cell Therapy to Transform Immune Cells into Cancer Fighters By www.medindia.net Published On :: A newly developed platform mimics nature to enhance immune-based treatments in the fight against medlinkcancer/medlink. h2Fighting Cancer from Full Article
hera Immunotherapy Breakthrough: 92% Survival for Hodgkin Lymphoma Patients By www.medindia.net Published On :: A new treatment that activates the immune system to fight cancer has boosted the survival rate for patients with advanced Hodgkin lymphoma to an impressive Full Article
hera Biomarker NBR1 Identifies Likely Immunotherapy Response in Liver Cancer By www.medindia.net Published On :: A preclinical study suggests it may soon be possible to determine which patients with hepatocellular carcinoma, a type of liver cancer, could benefit from immunotherapy. Full Article
hera Precision Oncology: Role of MeCo Score in Personalized Breast Cancer Therapy By www.medindia.net Published On :: Tissue stiffness in HER2-negative breast cancer, the most common type, can directly contribute to disease progression and metastasis, which can have serious consequences on patients. Full Article
hera Use of Mini-Proteins in Targeted Cancer Therapy By www.medindia.net Published On :: Mini-proteins are engineered protein capsule, bcapable of delivering targeted radiation dose directly to tumor cells expressing Nectin-4/b. Nectin-4 Full Article
hera HER2-Positive Breast Cancer Therapies Show Potential in Bile Duct Cancer Trials By www.medindia.net Published On :: Drugs aimed at HER2-positive breast cancer may also help certain patients with bile duct cancer, as indicated by findings from a patient trial that will Full Article
hera A New Light on Brain Injury: Near-Infrared Therapy Shows Promise By www.medindia.net Published On :: Light therapy administered through the skull was found to accelerate tissue recovery following mild traumatic brain injury (mTBI) (!--ref1--). Their Full Article
hera How Oncolytic Virotherapy Helped Beat Breast Cancer By www.medindia.net Published On :: Breast cancer is the most common cancer worldwide and it is the second leading cause of death in women. It mainly occurs in middle-aged and older women. Full Article
hera New Hope for Depression: Psychedelic Therapy Offers Promise By www.medindia.net Published On :: As mounting evidence supports the potential of psychedelic-assisted therapies, the FDA nears a groundbreaking decision: the approval of psilocybin, the Full Article
hera Virtual Therapy Helps Manage Depression and Anxiety By www.medindia.net Published On :: Remote video consultations with medlinkmental health/medlink specialists lead to a small yet meaningful improvement in symptoms of depression and anxiety (!--ref1--). Full Article
hera Gene Therapy Breaks Up New Dawn for Beta Thalassemia By www.medindia.net Published On :: With FDA approval, UCSF Benioff Children's Hospital Oakland pioneers gene therapy for beta thalassemia, a rare genetic blood disorder, potentially alleviating Full Article
hera Is Stem Cell Therapy Safe for Relapsing-Remitting Multiple Sclerosis Treatment? By www.medindia.net Published On :: Autologous hematopoietic stem cell transplantation or aHSCT, often used to treat medlinkblood cancers/medlink, was also demonstrated to be safe and Full Article
hera Is Stem Cell Therapy a Breakthrough for Reversing Osteoarthritis? By www.medindia.net Published On :: Researchers in Australia have identified a previously unknown population of stem cells fibroblast growth factor 18 (FGF18) stimulated Gremlin 1 cells, Full Article
hera World's First CRISPR-Based Gene Therapy for Blood Disorders By www.medindia.net Published On :: Nobel Prize-winning inventors of CRISPR, awarded in 2020, have seen their gene-editing tool gain approval in the UK for the first-ever therapy targeting Full Article
hera New Gene Therapy to Treat Genetic Brain Disorder By www.medindia.net Published On :: Two girls with a rare genetic brain disorder called Rett Syndrome was successfully treated by a first-ever novel gene therapy- NGN-401, developed by US-based Neurogene. Full Article
hera Mapping Genetic Mutations to Customize Preterm Birth Therapy By www.medindia.net Published On :: medlinkPregnant women/medlink with high levels of certain genetic mutations- especially those associated with involuntary muscle contraction - were less likely to respond to preterm treatment. Full Article
hera New Gene Therapy for Children With Genetic Epilepsy By www.medindia.net Published On :: CDD - CDKL5 deficiency disorder, a most common type of medlinkgenetic epilepsy/medlink in children, occurs due to the loss of genes producing the CDKL5 enzyme. Full Article
hera Stem Cell Therapy in Spinal Cord Injury Rehabilitation By www.medindia.net Published On :: Stem cell therapy emerges as a viable and safe choice for individuals grappling with challenging traumatic medlinkspinal cord injuries/medlink, said experts (!--ref1--). Full Article